Seres Therapeutics Stock News

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2021 Results - Earnings Call Transcript

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics press release (MCRB): FY GAAP EPS of -$0.72 misses by $0.10.Revenue of $144.92M (+334.8% Y/Y) misses by $4.9M.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2021 financial results and provided business updates. “The progress made throughout 2021 has set the stage for an exciting year ahead for Seres, highlighted by the anticipated BLA filing for SER-109 with the U.S. Food and Drug Administration (FDA) for recurrent C. difficile infection (rCDI) in mid-2022 which, if approved, we expect to

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (NASDAQ:MCRB) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is -$0.41 and the consensus…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 1, 2022 at 8:30 a.m. ET to discuss fourth quarter and full year 2021 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 6277858. To join the live webcast,

Seres Therapeutics Inc. (NASDAQ:MCRB) traded at $8.05 at close of the session on Friday, 02/18/22, made a downward move of -2.07% on its previous days price. Looking at the stock we see that its previous close was $8.22 and the beta (5Y monthly) reads 3.52 with the days price range being $7.93 $8.42. In Seres Therapeutics Inc. (NASDAQ: MCRB) Analysts Revisions Show Sentiment Is Improving Read More »

Phase 3 data from Seres Therapeutics on SER-109, its experimental oral microbiome therapeutic, showed it was superior to placebo in reducing C. difficile infection recurrence.

The increased focus on the development of human microbiome therapy is driving market expansion. It has also established itself as a viable target for therapeutic research. During the projection period, the expanding number of market player collaborations is likely to

Seres Therapeutics Inc. (NASDAQ:MCRB) has a beta value of 3.49 and has seen 1.57 million shares traded in the last trading session. The company, currently valued at $774.95M, closed the last trade at $8.53 per share which meant it gained $0.22 on the day or 2.65% during that session. The MCRB stock price is -250.53% Seres Therapeutics Inc. Is A Buy Small Cap Stock: Analysts Read More »

Related Stocks: KROS , CRNX , OPTN , SMLR , FOLD , MRUS , DTIL , AADI , NCNA , MGNX , SIOX , APTO , AVEO , EPIX , MCRB , CMLF , LUMO , KZR , CRDF ,

Equities research analysts expect that Seres Therapeutics, Inc. (NASDAQ:MCRB) will announce $19.48 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Seres Therapeutics earnings, with estimates ranging from $5.00 million to $58.30 million. Seres Therapeutics posted sales of $17.56 million during the same quarter last year, which []